Clinical trial
A Multi-center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects With Relapsed and/or Refractory Diffuse Large B Cell Lymphoma.
NCT07288879 is registered in ClinicalTrials.gov with Miltenyi Biomedicine GmbH as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects With Relapsed and/or Refractory Diffuse Large B Cell Lymphoma.
- Lead sponsor
- Miltenyi Biomedicine GmbH
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- December 11, 2025
- Completion date
- December 31, 2028
- Enrollment
- 31 (estimated)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
car t cell therapy, dlbcl - diffuse large b cell lymphoma